Prazover 20 mg (Capsule (Enteric Coated))

Unit Price: ৳ 5.01 (10 x 10: ৳ 501.00)

Strip Price: ৳ 50.10

Medicine Details

Category	Details
Generic	Omeprazole
Company	Veritas pharmaceuticals ltd
Also available as	Prazover dr 20 mg tablet Prazover 40 mg capsule

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Oral administration
Benign gastric and duodenal ulcer: 20 mg once daily for 4-8 weeks
NSAID-associated duodenal or gastric ulcer: 20 mg once daily for 4 weeks, maintenance dose for prevention of relapse in duodenal ulcer: 10-20 mg daily
Gastro-esophageal reflux disease: 20 mg once daily for 4-8 weeks, maintenance dose 20 mg once daily
Long-term management of acid reflux disease: 10-20 mg daily
Prophylaxis of acid aspiration: 40 mg on the preceding evening, then 40 mg 2-6 hours before surgery
Zollinger-Ellison syndrome: Initially 60 mg once daily, usual range 20-120 mg daily
Helicobacter pylori eradication regimen in peptic ulcer disease: Omeprazole is recommended at a dose of 20 mg twice daily in association with antimicrobial agents for one week
Pediatric use in severe ulcerating reflux esophagitis: 10-20 mg once daily for 4-12 weeks (if body-weight 10-20 kg) and 20-40 mg once daily for 4-12 weeks (if body-weight over 20 kg)
IV Injection: Prophylaxis of acid aspiration: Omeprazole 40 mg to be given slowly as an intravenous injection, one hour before surgery

IV Injection - for intravenous administration only
IV Infusion - intravenous infusion over a period of 20-30 minutes or more
Use of freshly prepared solution
Solution for IV injection should be given slowly over a period of at least 2 to 5 minutes at a maximum rate of 4 ml/minute

Decreased intragastric acidity affecting the absorption of ketoconazole
Metabolism through cytochrome P450 delaying the elimination of diazepam, phenytoin, and warfarin
Increase in plasma concentrations of Omeprazole and clarithromycin during concomitant administration
No evidence of interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxicillin, antacids, piroxicam, diclofenac, or naproxen
Increase in the bioavailability of digoxin during simultaneous treatment with Omeprazole

Mild and reversible adverse reactions
Skin rash, urticaria, pruritus, photosensitivity, bullous eruption, erythema multiforme
Diarrhea, headache, constipation, nausea/vomiting, flatulence, abdominal pain
Dry mouth, stomatitis, candidiasis, paraesthesia
Dizziness, light headedness, feeling faint, somnolence, insomnia, vertigo
Reversible mental confusion, agitation, depression, hallucinations
Arthritic and myalgic symptoms, blurred vision, taste disturbance, peripheral edema, increased sweating, gynaecomastia, leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, anaphylactic shock, malaise, fever, bronchospasm, encephalopathy, hepatitis, interstitial nephritis, hepatic failure
Increase in liver enzymes

No adverse effects of Omeprazole on pregnancy or on the health of the fetus/newborn child
Use during pregnancy permitted, no information available on passage into breast milk or effects on the neonate
Discontinuation of breast-feeding if essential use of Omeprazole